165 related articles for article (PubMed ID: 33906295)
1. Utilization of a Mixture Cure Rate Model based on the Generalized Modified Weibull Distribution for the Analysis of Leukemia Patients.
Omer ME; Abu Bakar M; Adam M; Mustafa M
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1045-1053. PubMed ID: 33906295
[TBL] [Abstract][Full Text] [Related]
2. Non-Mixture Cure Model Estimation in Bladder Cancer Patients: A Novel Approach with Exponentiated Weibull Exponential Distribution.
Omer ME; Mustafa M; Ali N; Abd Rahman NH
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4167-4177. PubMed ID: 38156852
[TBL] [Abstract][Full Text] [Related]
3. Cure fraction estimation from the mixture cure models for grouped survival data.
Yu B; Tiwari RC; Cronin KA; Feuer EJ
Stat Med; 2004 Jun; 23(11):1733-47. PubMed ID: 15160405
[TBL] [Abstract][Full Text] [Related]
4. Estimation method of the semiparametric mixture cure gamma frailty model.
Peng Y; Zhang J
Stat Med; 2008 Nov; 27(25):5177-94. PubMed ID: 18613271
[TBL] [Abstract][Full Text] [Related]
5. geecure: An R-package for marginal proportional hazards mixture cure models.
Niu Y; Wang X; Peng Y
Comput Methods Programs Biomed; 2018 Jul; 161():115-124. PubMed ID: 29852954
[TBL] [Abstract][Full Text] [Related]
6. Mixture and non-mixture cure fraction models based on the generalized modified Weibull distribution with an application to gastric cancer data.
Martinez EZ; Achcar JA; Jácome AA; Santos JS
Comput Methods Programs Biomed; 2013 Dec; 112(3):343-55. PubMed ID: 24008248
[TBL] [Abstract][Full Text] [Related]
7. The exponentiated exponential mixture and non-mixture cure rate model in the presence of covariates.
Mazucheli J; Coelho-Barros EA; Achcar JA
Comput Methods Programs Biomed; 2013 Oct; 112(1):114-24. PubMed ID: 23932336
[TBL] [Abstract][Full Text] [Related]
8. Applying conventional and saturated generalized gamma distributions in parametric survival analysis of breast cancer.
Yavari P; Abadi A; Amanpour F; Bajdik C
Asian Pac J Cancer Prev; 2012; 13(5):1829-31. PubMed ID: 22901130
[TBL] [Abstract][Full Text] [Related]
9. Bayesian mixture cure rate frailty models with an application to gastric cancer data.
Karamoozian A; Baneshi MR; Bahrampour A
Stat Methods Med Res; 2021 Mar; 30(3):731-746. PubMed ID: 33243085
[TBL] [Abstract][Full Text] [Related]
10. A generalized F mixture model for cure rate estimation.
Peng Y; Dear KB; Denham JW
Stat Med; 1998 Apr; 17(8):813-30. PubMed ID: 9595613
[TBL] [Abstract][Full Text] [Related]
11. Likelihood inference for COM-Poisson cure rate model with interval-censored data and Weibull lifetimes.
Pal S; Balakrishnan N
Stat Methods Med Res; 2017 Oct; 26(5):2093-2113. PubMed ID: 28656795
[TBL] [Abstract][Full Text] [Related]
12. Fitting parametric cure models in R using the packages cuRe and rstpm2.
Jensen RK; Clements M; Gjærde LK; Jakobsen LH
Comput Methods Programs Biomed; 2022 Nov; 226():107125. PubMed ID: 36126436
[TBL] [Abstract][Full Text] [Related]
13. Mixture cure model with random effects for the analysis of a multi-center tonsil cancer study.
Peng Y; Taylor JM
Stat Med; 2011 Feb; 30(3):211-23. PubMed ID: 21213339
[TBL] [Abstract][Full Text] [Related]
14. The beta modified Weibull distribution.
Silva GO; Ortega EM; Cordeiro GM
Lifetime Data Anal; 2010 Jul; 16(3):409-30. PubMed ID: 20238163
[TBL] [Abstract][Full Text] [Related]
15. Mixture and nonmixture cure fraction models assuming discrete lifetimes: Application to a pelvic sarcoma dataset.
de Oliveira RP; Menezes AFB; Mazucheli J; Achcar JA
Biom J; 2019 Jul; 61(4):813-826. PubMed ID: 30762893
[TBL] [Abstract][Full Text] [Related]
16. Models for Predicting Time to Sputum Conversion Among Multi-Drug Resistant Tuberculosis Patients in Lagos, South-West Nigeria.
Akinsola OJ; Yusuf OB; Ige OM; Okonji PE
Front Public Health; 2018; 6():347. PubMed ID: 30538978
[No Abstract] [Full Text] [Related]
17. Causal inference for time-to-event data with a cured subpopulation.
Wang Y; Deng Y; Zhou XH
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38708764
[TBL] [Abstract][Full Text] [Related]
18. Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses.
Cislo PR; Emir B; Cabrera J; Li B; Alemayehu D
Value Health; 2021 Nov; 24(11):1643-1650. PubMed ID: 34711365
[TBL] [Abstract][Full Text] [Related]
19. An extended cure model and model selection.
Peng Y; Xu J
Lifetime Data Anal; 2012 Apr; 18(2):215-33. PubMed ID: 22241600
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models.
Sayehmiri K; Eshraghian MR; Mohammad K; Alimoghaddam K; Foroushani AR; Zeraati H; Golestan B; Ghavamzadeh A
J Exp Clin Cancer Res; 2008 Nov; 27(1):74. PubMed ID: 19025609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
